cytochrome P450 family 2 subfamily D member 7 (gene/pseudogene)Genealiases: CYP2D · CYP2D7AP · CYP2D7P · CYP2D7P1 · CYP2D@ · P450C2D
Q-omics provides the consensus-scored CYP2D7 profile across patient tissues and cancer cell-line models. CYP2D7 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CYP2D7 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, CYP2D7 RNA expression shows 15,736 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, COAD, and UVM as cancer lineages where CYP2D7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP2D7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP2D7 survival associations across molecular data types. CYP2D7 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP2D7 RNA expression–survival associations across cancer types. High CYP2D7 expression shows unfavorable associations in ACC, KIRC and PRAD, but favorable associations in BLCA, HNSC and STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CYP2D7 RNA expression.
This table summarizes CYP2D7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CYP2D7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP2D7 shows lower tumor expression in BRCA and higher tumor expression in COAD, HNSC, KIRC, LUSC and UCEC. The COAD box plot shows higher CYP2D7 RNA expression in tumor versus normal tissue (log2 FC = +1.488, t-test p < 0.001).
This table shows molecular features associated with CYP2D7 in patient tissues and cancer cell lines. In patient samples, CYP2D7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP2D7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in STOMACH.
